Talk:Glembatumumab vedotin
Jump to navigation
Jump to search
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Glembatumumab vedotin.
|
Dec 2012 poster of EMERGE final results
The EMERGE study shows the results presented in Dec 2012. Its conclusions are :
"EMERGE results consistent with previous study in similar population * CDX-011 well-tolerated ‒ Less hematologic toxicity but more rash and neuropathy than Investigator’s Choice (IC) * Promising activity in triple-negative breast cancer (TNBC), where treatment options are limited ‒ CDX-011 response rate of 19% in TNBC compared to 0% for IC * Significant tumor expression of GPNMB associated with greater activity ‒ CDX-011 response rate of 32% compared to 13% for IC ‒ Stromal expression of GPNMB did not appear to correlate with outcome. ‒ High GPNMB expression in 41% of patients with TNBC ‒ CDX-011 response rate of 33% and doubling of PFS (p=0.008) and OS (p=0.003) * A registrational study is being planned."
Could mention PFS etc in main article. - Rod57 (talk) 00:46, 4 February 2013 (UTC)